Stage-specific expression of surface antigens by Toxoplasma gondii as a mechanism to facilitate parasite persistence.
Toxoplasma persists in the face of a functional immune system. This success critically depends on the ability of parasites to activate a strong adaptive immune response during acute infection with tachyzoites that eliminates most of the parasites and to undergo stage conversion to bradyzoites that encyst and persist predominantly in the brain. A dramatic change in antigenic composition occurs during stage conversion, such that tachyzoites and bradyzoites express closely related but antigenically distinct sets of surface Ags belonging to the surface Ag 1 (SAG1)-related sequence (SRS) family. To test the contribution of this antigenic switch to parasite persistence, we engineered parasites to constitutively express the normally bradyzoite-specific SRS9 (SRS9(c)) mutants and tachyzoite-specific SAG1 (SAG1(c)) mutants. SRS9(c) but not wild-type parasites elicited a SRS9-specific immune response marked by IFN-gamma production, suggesting that stage-specificity of SRS Ags determines their immunogenicity in infection. The induction of a SRS9-specific immune response correlated with a continual decrease in the number of SRS9(c) cysts persisting in the brain. In contrast, SAG1(c) mutants produced reduced brain cyst loads early in chronic infection, but these substantially increased over time accompanying a hyperproduction of IFN-gamma, TNF-alpha, and IL-10, and severe encephalitis. We conclude that stage-specific expression of SRS Ags is among the key mechanisms by which optimal parasite persistency is established and maintained.
Kim
Seon-Kyeong
SK
Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA 94305, USA.
Boothroyd
John C
JC
D000818:Animals; D000953:Antigens, Protozoan / Q000096:biosynthesis* / Q000235:genetics / Q000502:physiology; D000954:Antigens, Surface / Q000096:biosynthesis* / Q000235:genetics / Q000502:physiology; D002478:Cells, Cultured; D002908:Chronic Disease; D016207:Cytokines / Q000096:biosynthesis; D005260:Female; D006790:Host-Parasite Interactions / Q000235:genetics / Q000276:immunology; D007371:Interferon-gamma / Q000096:biosynthesis; D016753:Interleukin-10 / Q000096:biosynthesis; D051379:Mice; D008808:Mice, Inbred CBA; D009154:Mutation; D015800:Protozoan Proteins / Q000096:biosynthesis* / Q000235:genetics / Q000502:physiology; D016052:Protozoan Vaccines / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology; D013154:Spleen / Q000276:immunology / Q000378:metabolism / Q000469:parasitology; D014122:Toxoplasma / Q000235:genetics / Q000254:growth & development* / Q000276:immunology*; D014124:Toxoplasmosis, Animal / Q000276:immunology* / Q000401:mortality / Q000469:parasitology* / Q000517:prevention & control; D016781:Toxoplasmosis, Cerebral / Q000276:immunology* / Q000401:mortality / Q000469:parasitology* / Q000517:prevention & control
D000953:Antigens, Protozoan; D000954:Antigens, Surface; D016207:Cytokines; D015800:Protozoan Proteins; D016052:Protozoan Vaccines; C047168:SAG1 antigen, Toxoplasma; D016753:Interleukin-10; D007371:Interferon-gamma